JAGSNPHARMPharmaceuticals
Jagsonpal Pharmaceuticals Ltd — PE Ratio & Valuation Analysis
₹184.03
+0.05%
Current P/E33.23xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E46.3x28.3% below avg
⚠️
4.6% Premium to Industry
JAGSNPHARM P/E 33.23x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹8.22 | ₹193 | 23.4x |
| 2024 | ₹3.39 | ₹244 | 72.1x |
| 2023 | ₹4.08 | ₹156 | 38.1x |
| 2022 | ₹2.88 | ₹149 | 51.8x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Jagsonpal Pharmaceuticals Ltd Valuation
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) currently trades at 33.23x earnings. The Pharmaceuticals sector average PE is 31.77x. JAGSNPHARM commands a premium, reflecting high growth expectations. Historically, JAGSNPHARM has traded at an average PE of 46.3x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
18.58%
Dividend Yield
1.15%
More on Jagsonpal Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.